Capilea Mexico Unveils New Insights on Surge of US Patients Choosing Mexico for Hair Transplants

Capilea Mexico Unveils New Insights on Surge of US Patients Choosing Mexico for Hair Transplants




Capilea Mexico Unveils New Insights on Surge of US Patients Choosing Mexico for Hair Transplants

Mexico: The New Hub for US Hair Transplants

Tijuana, BC, Dec. 26, 2025 (GLOBE NEWSWIRE) — Capilea Mexico, a leading hair restoration clinic network in Latin America, today unveiled new insights highlighting Mexico’s emergence as a top destination for US patients seeking hair transplants. The findings point to a growing trend in medical tourism, driven by geographic proximity, lower procedure costs, and increasing trust in Mexico’s advanced hair restoration clinics.Capilea Mexico Unveils New Insights on Surge of US Patients Choosing Mexico for Hair Transplants

Dr. Héctor Treviño – Medical Director of Capilea Mexico

In recent years, medical tourism has seen a significant rise, particularly in the field of hair transplants. Mexico has emerged as a leading destination for US residents seeking high-quality and affordable hair restoration services. This shift is driven by several key factors that position Mexico as a compelling alternative to domestic options and traditional international destinations like Turkey.

According to recent analyses, Mexico’s strategic location and competitive pricing have solidified its position as a top choice for American patients. The geographic proximity of Mexico offers ease of travel and reduced travel time compared to more distant options, making it an attractive choice for those seeking convenience.

Cost-effectiveness is another major advantage. Mexican clinics offer significantly lower prices for high-quality procedures compared to the US, without compromising on results. This affordability, combined with advanced techniques and skilled specialists, ensures that patients receive exceptional care.

While Turkey continues to attract a significant number of European clients, Mexico has rapidly gained traction among Americans. This trend highlights Mexico’s specific advantage for the US market, offering a superior solution for residents who might be weighing options like flying to Turkey versus driving to Mexico.

Among the leading institutions, Capilea stands out for its exceptional patient care and innovative techniques. Other highly reputable clinics such as Nader Medical and Dr. Angelina Vargas also contribute to Mexico’s growing reputation as a hair transplant hub.

“Mexico’s emergence as a premier destination for hair transplants is a testament to our commitment to quality and patient satisfaction,” says Dr. Héctor Treviño, Medical Director of Capilea.

Insights from US search trends related to “Turkey hair transplant” indicate a growing interest in alternative destinations. Mexico offers a compelling solution for US residents, providing high-quality care closer to home.

As Mexico continues to establish itself as a leader in the hair transplant industry, potential patients are encouraged to explore the top clinics listed for more information. This development not only restores hair but also confidence, offering world-class solutions with a personal touch.

Capilea Mexico Unveils New Insights on Surge of US Patients Choosing Mexico for Hair Transplants

male patient before and after

About Capilea Mexico

Capilea is a premier hair restoration medical center with over 25 years of experience, operating state-of-the-art clinics across Latin America and Spain. The center is renowned for its expertise in advanced FUE hair transplant procedures, as well as PRP therapy and specialized hair loss treatments. Headquartered in Mexico, Capilea runs modern facilities in Monterrey, Tijuana, and Mexico City. Led by distinguished specialists—Dr. Héctor Treviño, Dr. Carlos Rodríguez, and Dr. Benjamín Pérez—Capilea has successfully treated over 11,550 hair graft patients, restoring more than 52,120,000 strands of hair for both domestic and international clients. Its team of certified professionals delivers comprehensive, premium-quality care using the latest advances in technology. With a growing footprint throughout Latin America and now Spain, Capilea remains dedicated to restoring not just hair, but also patient confidence, providing world-class hair restoration solutions with a personal touch. 

Press inquiries

Capilea Mexico
https://capileamexico.com/en/
Dr. Héctor Treviño
admin@capileamexico.com
NewCity Medical Plaza
P.º del Centenario 9580-Piso 2106, Zona Urbana Rio Tijuana

Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations

Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations




Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations

While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz

FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comments by Robert J. Hariri, M.D., Ph.D., CEO and Chairman, on the Centers for Medicare & Medicaid Services’ (CMS) recent withdrawal of skin substitute Local Coverage Determinations (LCDs) that were set to go into effect on January 1, 2026.

On December 24, 2025, CMS announced that effective immediately, A/B Medicare Administrative Contractors (MACs) were withdrawing the LCDs for Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers scheduled to become effective on January 1, 2026. The LCDs, adopted under an earlier Medicare 2026 Skin Substitute Update, set which skin substitute products would be eligible for Medicare coverage beginning in 2026. While Celularity’s Biovance® and Biovance 3L remained eligible for Medicare coverage under the now-withdrawn LCDs, Medicare coverage was eliminated for 158 skin substitute products sold by other companies. Unaffected by CMS’ recent action is its new payment policy that effective January 1, 2026, all skin substitute applications furnished in physician office settings and hospital outpatient department settings will be paid at a flat rate of $127.28 per square centimeter.

Commenting on the recent change, Dr. Hariri said, “We have amassed substantial real-world evidence, or RWE, from multiple studies showing how our Biovance® Human Amniotic Membrane Allograft works in actual clinical practice for wound healing, demonstrating its effectiveness in diverse, real-life diverse patient populations patients with chronic wounds. RWE from large observational studies published in the peer-reviewed journal WOUNDS and elsewhere show Biovance® effectively treats chronic wounds, even in patients with multiple health issues. Other RWE shows reduced steroid use in about half of patients treated with Biovance®, which evidence indicates helps decrease pro-inflammatory factors and increase anti-inflammatory ones, guiding the body’s natural healing.”

Dr. Hariri noted that CMS’ 2026 Medicare payment policy setting skin substitute reimbursement at a flat $127.28 per square centimeter remains in effect despite it withdrawing the LCDs. “Biovance® has been supported by a highly efficient, proven scalable manufacturing process since its commercial launch in April 2014, which today allows us to operate comfortably under the new Medicare reimbursement for skin substitute products,” he said. “Our sustained investment in advanced infrastructure includes a world-class GMP/GTP manufacturing facility located in Florham Park, New Jersey, where today we manufacture a range of commercial advanced biomaterial products and investigational cell therapy products, including both Celularity branded products and contract manufactured products for third parties. Consistent with our emphasis on real-world evidence gained from actual clinical use of our products, we have integrated an ‘Industry 5.0’ approach into our manufacturing operations, introducing digitization and AI and building adaptable and robust value chains and production systems,” Dr. Hariri said.

About Celularity

Celularity Inc. (Nasdaq: CELU) is a regenerative and aging-related cellular medicine company developing, manufacturing, and commercializing advanced biomaterial products and allogeneic and autologous cell therapies, all derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies that target fundamental aging mechanisms like cellular senescence, age-related chronic inflammation, and tissue degeneration. For more information about Celularity and its cutting-edge regenerative medicine solutions, please visit www.celularity.com.

Forward Looking Statements

Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding: (i) Celularity’s ability to execute its strategic priorities, including leveraging its placental-derived platform and aligning its operations and organizational focus with those priorities; (ii) Celularity’s plans to emphasize applications related to longevity and age-related disease; and (iii) the anticipated impact and benefits of the financing transactions on Celularity’s business and strategic flexibility. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “improving,” “may,” “observed,” “potential,” “promise,” “should,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Celularity’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K and Form 10-K/A for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on May 8, 2025 and May 21, 2025, respectively, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Carlos Ramirez

Senior Vice President, Celularity Inc.

Carlos.ramirez@celularity.com

Arcadia Biosciences (RKDA) Receives Termination Notice of the Proposed Business Combination with Roosevelt Resources

Arcadia Biosciences (RKDA) Receives Termination Notice of the Proposed Business Combination with Roosevelt Resources




Arcadia Biosciences (RKDA) Receives Termination Notice of the Proposed Business Combination with Roosevelt Resources

DALLAS, Dec. 26, 2025 (GLOBE NEWSWIRE) — Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today announced that on December 24, 2025, it received a notice from Roosevelt Resources, LP, terminating the Securities Exchange Agreement between Arcadia and Roosevelt dated December 4, 2024, pursuant to the terms of the agreement. The agreement provided for a proposed business combination transaction between the two companies.

“In light of these circumstances, Arcadia will resume the process of evaluating strategic alternatives in order to create value for our shareholders.” said T.J. Schaefer, CEO of Arcadia.

Schaefer continued, “Over the last two-and-a-half years, we have streamlined our operations, significantly reduced our operating expenses and grown the Zola® coconut water brand while avoiding the use of long-term debt. We continue to own approximately 2.7 million shares of Above Food Ingredients Inc. common stock and believe we are entitled to additional consideration and compensation relating to our May 2024 sale of GoodWheatTM. We believe these assets, along with our Nasdaq public listing and our Zola business, should make Arcadia an attractive candidate for a merger or other strategic transaction.”

About Arcadia Biosciences, Inc.
Since 2002, Arcadia Biosciences (Nasdaq: RKDA) has been innovating high-value, healthy ingredients to meet consumer demands for healthier choices. With its roots in agricultural innovation, Arcadia cultivates next-generation wellness products. For more information, visit www.arcadiabio.com.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets, or future developments or otherwise are not statements of historical fact. These statements relate to future events or future results of operations, including, but not limited to statements concerning the following matters: the company’s anticipated financial position, cash needs and ability to continue operations; the company’s beliefs concerning its ability to pursue and enter into alternative strategic transactions and its attractiveness as a candidate for a strategic transaction; the company’s beliefs concerning its entitlement to additional shares of common stock of Above Foods Ingredients Inc. (“ABVE”) and concerning principal and interest payments owed by Above Foods Corp.; and the company’s beliefs concerning the availability of adequate funding to support the company’s future operations from available cash resources, revenues from future sales of products, proceeds from sales of assets including shares of ABVE that it holds (if such shares may be sold pursuant to Rule 144 or otherwise), sale of equity or debt securities, or other transactions. Forward-looking statements concerning anticipated future activities assume that the company has sufficient funding to continue its operations and planned activities, which may not be the case. Arcadia will require additional funding in the near future to continue its operations and planned activities. There are no assurances that required funding will be available at all or will be available in sufficient amounts or on reasonable terms. The company may seek to raise additional funds through equity or debt financings. Any sale of additional equity securities could result in material dilution to company stockholders. If the company is not able to secure adequate additional funding, it could be required to reduce or suspend activities, liquidate assets, or initiate dissolution and liquidation or bankruptcy proceedings. In the event of such proceedings, Arcadia’s creditors would have first claim on the value of the company’s assets which, other than remaining cash, would most likely be liquidated in one or more transactions or a bankruptcy sale, and the common stock of Arcadia likely would have little or no value. Any of these actions would have a material adverse effect on its business, results of operations and financial condition. Forward-looking statements are only predictions and involve known and unknown risks, uncertainties, and other factors that may cause the company’s actual results to be materially different from the results anticipated by such forward-looking statements. Undue reliance should not be placed on any forward-looking statements. Risks and uncertainties relating to the company’s business and future prospects also include, but are not limited to, the risks set forth in filings that the company makes with the Securities and Exchange Commission (SEC) from time to time, including in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2024, as amended, quarterly reports on Form 10-Q filed with the SEC during the 2025 year, the registration statement on Form S-4 initially filed with the SEC on February 14, 2025 and amended July 31, 2025, and other filings that the company makes with the SEC, all of which are available free of charge on the SEC’s web site at http://www.sec.gov. Further, any forward-looking statement speaks only as of the date as of which it was made, and except as required by law, Arcadia Biosciences, Inc. disclaims any obligation to update forward-looking statements or to reflect events or circumstances arising after the date of this press release.

Arcadia Biosciences Contact:
T.J. Schaefer
ir@arcadiabio.com

IBA signs contract for a three-room Proteus®PLUS solution to be installed at the Seoul St. Mary’s Hospital

IBA signs contract for a three-room Proteus®PLUS solution to be installed at the Seoul St. Mary’s Hospital




IBA signs contract for a three-room Proteus®PLUS solution to be installed at the Seoul St. Mary’s Hospital

Louvain-La-Neuve, Belgium, December 26, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract with the Catholic University of Korea, Seoul St. Mary’s Hospital, one of the largest hospital in South Korea, for a Proteus®PLUS1 solution to be installed in Seoul.

The contract includes the equipment of a Proteus®PLUS solution with three gantry-room as well as a multi-year service contract. The system will also include DynamicARC®2 beam delivery capabilities, once this feature has received regulatory clearance.

The Seoul St. Mary’s Hospital plans to begin patient treatments by the end of 2029. Upon full completion, the center will have eight floors, including underground levels, and a total area of 37,851 square meters.

Olivier Legrain, Chief Executive Officer of IBA, commented: “We are pleased to partner with Seoul St. Mary’s Hospital to bring the latest proton therapy technology in South Korea, expanding the number of centers in the country that benefit from IBA’s proton therapy solutions. This contract highlights the relevance of our offering in markets where demand for this cutting-edge treatment modality is strongly increasing. We look forward to working with the expert medical team of Seoul St. Mary’s to make this technology more accessible to patients.”

LEE Ji Youl, MD, PhD, President of Seoul St. Mary’s Hospital, added: “We are pleased to have signed this contract with IBA, the world leader in proton therapy technology, for the introduction of cutting-edge latest-generation equipment. The construction of the center is the final step in completing the Seoul St. Mary’s Hospital complex. Our hospital will provide world-best treatment not only in the field of blood cancers, for which it has earned a global reputation, but also in the treatment of solid tumors.

The typical end-user price for a three-room Proteus®PLUS system with a multi-year maintenance contract ranges between € 80 and 100 million.

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

About Seoul St Mary’s Hospital

Seoul St. Mary’s Hospital is one of Korea’s top academic hospitals and the flagship institution of the Catholic Medical Center. It provides comprehensive care across 45 departments and 27 specialized centers, including the Cardio-Cerebro-Vascular Hospital, Catholic Hematology Hospital, and Comprehensive Cancer Hospital. With pioneering achievements such as Korea’s first kidney and bone marrow transplants and Korea’s first artificial cornea transplant, the hospital provides world-class care. Trusted by both domestic and international patients, Seoul St. Mary’s Hospital has treated over 30,000 international patients from more than 100 countries. The hospital continues to enhance the quality of its services and has trained more than 900 international physicians through its fellowship programs.

For further information, please contact:

IBA Investor Relations
Thomas Pevenage
+32 10 475 890
investorrelations@iba-group.com
IBA Corporate Communication
Olivier Lechien
+32 10 475 890
communication@iba-group.com


1 Proteus®PLUS is a brand name of Proteus®235.

2 DynamicARC® is a registered brand of the IBA’s Proton Arc therapy solution currently under development phase.

Attachment

XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency




XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) — XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated December 22, 2025, notifying the Company that based on XTL’s closing bid price for the last 30 consecutive business days, the Company currently does not meet the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share.

The Nasdaq notification letter does not result in the immediate delisting of the Company’s American Depositary Shares (“ADSs”), and the ADSs will continue to trade uninterrupted under the symbol “XTLB”.

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until June 22, 2026, to regain compliance. If at any time during this 180-day period the closing bid price of the Company’s security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide XTL with written confirmation of compliance and this matter will be closed.

In the event the Company does not regain compliance, XTL may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If XTL meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that its securities will be subject to delisting.

XTL is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirements. Although XTL will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirements.

About XTL Biopharmaceuticals Ltd.

XTL is an IP portfolio company.  XTL holds 100% of the share capital of The Social Proxy Ltd. (the “Social Proxy”), a web data company, and has sublicensed out an IP portfolio surrounding hCDR1 for the treatment of Lupus disease. The Social Proxy is a web data AI company, developing and powering a unique ethical, IP based, proxy data extraction platform for AI and BI applications at scale.

Cautionary Note Regarding Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this communication that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of the Company and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to (i) whether to the Company will be able to receive sub-licensing fees relating to its Hcdr1 intellectual property, (ii) the Company’s ability to successfully manage and integrate The Social Proxy and any other joint ventures, acquisitions of businesses, solutions or technologies; (iii) unanticipated operating costs, transaction costs and actual or contingent liabilities; (iv) the ability to attract and retain qualified employees and key personnel; (v) adverse effects of increased competition on the Company’s future business; (vi) the Company’s ability to protect its intellectual property; and (vii) local, industry and general business and economic conditions. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 20-F and current reports on Form 6-K filed by the Company with the Securities and Exchange Commission. The Company anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. The Company assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing the Company’s plans and expectations as of any subsequent date.

For further information, please contact:

Investor Relations, XTL Biopharmaceuticals Ltd.
Tel: +972 3 611 6666
Email: info@xtlbio.com
www.xtlbio.com

LULUTOX Detox Tea in Consumer Coverage as Website Update Introduces More Transparency in Herbal Digestive Supplement Information

LULUTOX Detox Tea in Consumer Coverage as Website Update Introduces More Transparency in Herbal Digestive Supplement Information




LULUTOX Detox Tea in Consumer Coverage as Website Update Introduces More Transparency in Herbal Digestive Supplement Information

A summary of the current discussions in consumer health and wellness on the topic of LULUTOX Detox Tea

New York City, NY, Dec. 24, 2025 (GLOBE NEWSWIRE) —  With the ongoing popularity of digestive wellness and daily detox in the popular health and lifestyle discourse, the consumer-facing media has begun to take a closer look at how the topic of herbal supplements is framed, regulated, and interpreted by the general public. In this respect, LULUTOX Detox Tea has declared a modification of its official site, which will help to present a more definite picture of its caffeine-free herbal tea supplement and its purpose as a component of a general wellness program.
Visit Now Official Site

The update of the site is in the context of the ongoing consumer interest in the products that are placed in the digestive balance and internal cleansing. Instead of launching a new formulation or product line, the update is aimed at the availability of information, ingredient disclosure, and use recommendations to people who want to learn more about non-prescription herbal supplements.

Broadening: Digestive Health and Social Welfare regarding the Detox Practices

Within the last few years, the issue of digestive health acquired the leading position in the list of the activity of the wellness discussion because of lifestyle changes, diet, stress, and the increased popularity of gut-related disorders, such as bloating and irregular digestion. As a result, many solutions such as altering diet and probiotics and herbal teas are researched by a large population to get them more at ease within their digestive system.

LULUTOX Detox Tea Explore It To Know More

The detox teas, specifically, are in a specialized niche in this landscape. Historically linked with herbal traditions, these teas are commonly placed as mild, routine-based supplements instead of intensive cleansing protocols. The role of consumer reporting in 2025 is likely to focus more on the need to make a difference between the traditional wellness products and medical interventions as the level of scrutiny of the health claims by the population is expected to increase.

LULUTOX Detox Tea is mentioned in the context of this general discussion as a caffeine-free herbal tea supplement that is to be used on a daily basis. Consumer coverage does not define the product as a medical treatment, therapeutic solution, or a replacement of professional healthcare.

The Web Site Revision and Its Object

The updated LULUTOX site, according to publicly available information, is to display more structured and accessible information on the formulation of the product, its preparation, and overall usage. The update is an indication of a wider trend in the supplement industry towards more direct communication and consumer education.

Instead of emphasizing the use of promotional messages, the site describes the fundamental product features, such as its herbal tea form, caffeine-free make-up, and the ability to prepare it either hot or cold. This kind of information enables consumers to make personal decisions about the product better informed on what the product is and what it is not.

The focus on transparency is in line with the changing consumer expectations. Consumers are also demanding more transparency regarding the use of supplements especially in the area of detox and digestion where falsehoods can be so easily created.

The interpretation of LULUTOX Detox Tea as Dietary Supplement

LULUTOX Detox Tea is defined as a nutritional supplement that is provided in the shape of herbal tea bags. Like all dietary supplements in the United States, it functions under a different regulatory framework as pharmaceuticals. Dietary supplements are not authorized to diagnose, treat, cure or prevent disease and are controlled based on labeling accuracy and safety standards and not based on pre-market efficacy.

Now Time to Order the LULUTOX Detox Tea and Save Big

Articles about LULUTOX focusing on consumers always recognize this difference. The product is presented as a wellness supplement that should be used to supplement daily activities, not a medical fix to digestive disorders or system detoxification.

This framing is especially significant in the detox category, where words may be interpreted to suggest a physiological cleansing that is not already done by the body. Neutral reporting does not imply such implications, as it is directed towards general wellness context.

Ingredient Disclosure and Traditional Use Context

The publicly accessible accounts of LULUTOX Detox Tea mention a combination of herbs, which are traditionally linked to the comfort of the digestive system and the daily well-being. Although individual herbs might have a history of traditional use, consumer coverage observes that traditional use is not similar to clinical validation.

The new site includes ingredient information to enable the consumers to see the formulation on their own. The strategy is conducive to making informed choices and is consistent with the larger consumer education campaigns that make people aware of what they are eating.

Notably, neutral reporting does not claim that certain ingredients have certain guaranteed effects. The studies on herbs tend to be context-dependent, and the findings of the controlled studies or traditional use might not directly apply to the commercial use of supplements.

Standards and Quality of Manufacturing

LULUTOX Detox Tea is said to be produced in the plants that comply with the general quality and safety standards that are used in relation to dietary supplements. Although adherence to manufacturing standards is a regulatory necessity, consumer coverage stresses the point that adherence to manufacturing standards does not mean clinical efficacy.

The reference to manufacturing standards is mostly used to assure consumers that there are minimum regulatory requirements that are satisfied. It is not a recommendation of results or performance.

Visit the Official Website

With the rise in consumer awareness, there is a rise in the demand to know more about the production of supplements, particularly their origin. This is a wider trend of accountability and transparency in the wellness industry, which is reflected in the addition of manufacturing information.

Public Scrutiny and Consumer Feedback

Alongside the official product descriptions, the online views and third-party commentary are becoming more and more influential in the way the supplements are perceived by the mass audience. Articles that are consumer-oriented and analyze LULUTOX Detox Tea mention that there are mixed views, which represent a variety of personal experiences.

This coverage usually warns the reader not to take anecdotal views as conclusive. The dietary supplements may have a wide range of experiences based on the individual physiology, diet, hydration and lifestyle.

The use of neutral reporting makes readers perceive feedback as personal narrative and not clinical evidence. This moderation strategy can avoid overgeneralization and facilitate realistic expectations.

Gastrointestinal Health, Cleanse, and Myths

The necessity to dispel the widespread misconceptions is one of the themes that can be repeated in consumer education on detox products. Health experts often mention that the human body already has its own efficient detoxification mechanisms, which are the liver, the kidneys and the digestive tract.

In this regard, the products like LULUTOX Detox Tea are discussed as wellness facilitators, not physiological ones. Consumer coverage is the fact that these products are not aimed to replace healthy food, drink, or medical treatment.

This explanation is especially important considering the popularity of detox language in marketing. The neutral press coverage aims at placing such language in context and strengthening evidence-based knowledge.

The Uses of Caffeine-Free Herbal Teas in the Daily Routines

Herbal teas with no caffeine have a niche in the everyday wellness routine. They are used by many people as part of a regimen to hydrate, relax or to aid in digestion. Consumer observes that lack of caffeine can be of value to those who are sensitive to stimulant or those who want to use it in the evening.

The LULUTOX Detox Tea is presented within this category where its main characteristic is in the format of tea instead of the use of capsules or powder. This difference is important to consumers who like conventional ways of making tea or those who have a connotation of tea preparation as a daily habit and moderation.

Customer Warranties and Customer Guarantees

The information that is publicly available points out that LULUTOX Detox Tea provides a satisfaction guarantee to the customers who have newly joined the company. Consumer coverage relates such policies to normal commercial practices, but not to a product performance indicator.

Exclusive offers, visit the official LULUTOX website

The issue of guarantees is addressed with respect to consumer protection, and people have an opportunity to make a wise choice in terms of buying goods. The neutral reporting does not interpret the guarantees as effectiveness.

The Regulatory Environment and Accountable Communication

The food supplement industry is regulated with an aim of guaranteeing safety and accurate labeling. Nevertheless, the supplements do not have to prove their effectiveness before entering the market. Commercial coverage that mentions LULUTOX Detox Tea indicates increased awareness of the difference in society.

Accountable communication, especially in the press releases, involves the use of responsible language that does not suggest health benefits. The update on the LULUTOX site seems to be consistent with this strategy, as it is descriptive and does not involve outcome-related statements.

Expansive Wellness Communication Implications

The focus on the update of the LULUTOX Detox Tea website is a part of a widespread tendency of wellness brands to address the consumer. More and more, it is being acknowledged that trust can be established by being clear, restrained and respectful of consumer intelligence instead of promoting aggressively.

The role of neutral press coverage in this ecosystem is to put products into context in bigger trends as opposed to trending up marketing stories. By so doing, it will help in making informed civic dialogue regarding wellness options.

Frequently Asked Questions

1- What is LULUTOX Detox Tea, by consumer coverage?

According to consumer-based reporting, LULUTOX Detox Tea is a herbal-based caffeine-free tea supplement that falls under the category of digestive wellness and daily detox products. It is also introduced as a non-prescription commodity to be used in general wellness as opposed to a medical treatment or therapeutic intervention.

2- Does the press release purport that LULUTOX Detox Tea is a medical detoxification?

No. The press release is not arguing that LULUTOX Detox Tea is medically detoxifying the body and it is substituting the natural mechanism of body detoxification. It has a clear difference between wellness oriented herbal supplements and clinical or medical detox treatments and has highlighted the major role played by body organs like liver and kidneys in undertaking the various body functions of detox.

3- Why has LULUTOX Detox Tea appeared in the eyes of consumers in 2025?

The LULUTOX Detox Tea is among those that have been mentioned in the consumer conversations with the current social concerns in relation to the digestive health, bloating prevention, and wellness routine. Its reference indicates a wider interest in herbal teas and supplements as opposed to approval or clinical support.

4- Do the ingredients of LULUTOX Detox Tea have scientifically proven results to achieve certain outcomes?

The press release does not insist that the ingredients or formulation has been scientifically tested to provide certain digestive or detox effects. Although the history of some herbs has been a record of tradition, consumer coverage reminds that the research of an ingredient in its traditional form or a single ingredient does not necessarily yield the same results when used as a commercial supplement.

5- Who is advised to consult a professional with regards to the use of detox tea supplements?

People who have underlying medical issues, take any prescription drugs, are pregnant or lactating or have any health related issues are advised to first seek the advice of a qualified health care specialist before taking any dietary supplement, herbal detox teas. This is an indication of overall best-practice guidelines within the supplement industry.

Conclusion

The new look of the LULUTOX Detox Tea site and the following news on a consumer oriented media underline that there has been continuous activity in the wellness industry to enhance transparency and communication. LULUTOX Detox Tea is being marketed as a caffeine-free herbal tea supplement, designed to support general digestive and wellness without making any medical claims or guaranteeing results.

With the product placed in the wider contexts of digestive health, detox myths, regulatory framework, and customer education, coverage focuses on education rather than advertising. With the growing popularity of wellness supplements among the general population, this form of balanced reporting is the only way to help people maneuver in an ever-growing marketplace.

Company: LULUTOX Detox Tea 

Email: support@lulutox.com

Phone: +1(888) 828-8953

Website: https://shop.lulutox.com/

Attachment

CONTACT: Company: LULUTOX Detox Tea 

Email: support@lulutox.com

Phone: +1(888) 828-8953

Website: https://shop.lulutox.com/

Relapse Risk Increases During the Holidays; Desert Hope Treatment Center Urges Early Support

Relapse Risk Increases During the Holidays; Desert Hope Treatment Center Urges Early Support




Relapse Risk Increases During the Holidays; Desert Hope Treatment Center Urges Early Support

LAS VEGAS, Dec. 24, 2025 (GLOBE NEWSWIRE) — This holiday season, addiction experts at Desert Hope Treatment Center are encouraging individuals in recovery to stay connected to support, as research shows drug and alcohol relapse rates spike during the holidays. Factors such as heightened emotional stress, disrupted routines, social pressures, and isolation contribute to an increased risk of relapse, especially when early warning signs are overlooked.

Clinicians at Desert Hope note that relapse often begins mentally before any physical return to substance use occurs. Recognizing the warning signs early and reaching out for help can be critical for protecting recovery.

Common warning signs include:

  • Increased cravings or persistent thoughts about using
  • Romanticizing past substance use or minimizing its consequences
  • Pulling away from support systems, meetings or loved ones
  • Increased anxiety, depression, irritability or emotional numbness

“The holidays can intensify emotional stress, even for people who have been stable in recovery for some time,” said Ariann Chelli, Clinical Director, Desert Hope Treatment Center. “Asking for help is not failure. Addiction is a chronic, progressive disease. It’s important to reach out before a relapse occurs. For some, that may mean leaning on additional support. For others that may mean returning to treatment for a period of time.”

Clinicians at the Nevada drug rehab stress that the risk of relapse increases when individuals delay seeking help or minimize early warning signs. Many notice mental and emotional shifts weeks before a relapse but wait until reaching a crisis point to reach out.

Desert Hope Treatment Center reminds individuals in recovery, their families, and community members that support is available throughout the holiday season. Alumni of Desert Hope programs are also encouraged to reconnect through the AAC Together app if they feel challenged or need additional support.

“We want people who are struggling to know our doors are always open,” said Chelli.

About Desert Hope Treatment Center
Desert Hope Treatment Center, located in Las Vegas, NV, serves the greater Las Vegas area and individuals nationwide with evidence-based addiction and mental health treatment. We provide a full continuum of inpatient and outpatient services, as well as sober living, for individuals facing substance use and co-occurring mental health disorders. We believe in the power of recovery and are committed to restoring hope, empowering individuals and families, and breaking the stigma of addiction. Our specialized programs, including tailored support for Veterans, offer a strong foundation for lasting recovery that transforms lives. Desert Hope Treatment Center is part of American Addiction Centers, a national leader in addiction treatment. Learn more at deserthopetreatment.com.

Desert Hope Contacts

Joy Sutton
American Addition Centers
VP of Brand and Communications
jsutton@contactaac.com

Profound Medical Corp. Announces Upsize of Private Placement

Profound Medical Corp. Announces Upsize of Private Placement




Profound Medical Corp. Announces Upsize of Private Placement

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement previously announced on December 19, 2025 (the “Offering”) in order to accommodate participation by a long-term existing investor.

The Company will now raise gross proceeds of up to US$6.45 million in the Offering, through the issuance of up to 921,428 common shares at a price of US$7.00 per common share.

The common shares sold pursuant to the Offering will be subject to a hold period of four months plus one day from the closing date of the Offering. The closing of the Offering is expected to occur on or prior to December 30, 2025.

The Company intends to use the net proceeds from the Offering for expansion of its sales and marketing, working capital, research and development, strategic transactions and general corporate purposes.

No securities will be sold under the Offering to United States purchasers and this press release is not an offer to sell or the solicitation of an offer to buy such securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered under the Offering have not been, nor will they be, registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

Forward-Looking Statements

This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, statements relating to the Company’s anticipated use of proceeds and the closing of the Offering. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound’s Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at www.sedarplus.ca and www.sec.gov. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

For further information, please contact:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849

ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®




ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it received an Incomplete Letter from the United States Food and Drug Administration (FDA) on December 23, 2025 for its Re-Tain® New Animal Drug Application (NADA), and simultaneously that it is increasing its First Defense® field sales force by 50% and expanding its First Defense® manufacturing capabilities.

In seeking FDA approval to bring its innovative Re-Tain® product to market, ImmuCell received Complete Letters from the FDA for four of the five Technical Sections required for NADA approval. It pursued a two-pronged manufacturing approach to reduce capital expenditure and limit technical risk for the remaining fifth Technical Section pertaining to manufacturing. ImmuCell manufactured the active pharmaceutical ingredient using a proprietary process in its own facility and hired an experienced contract manufacturer with FDA approvals for animal health products for the aseptic filling of the product into syringes. ImmuCell passed FDA inspection of its own facility in 2024. It is ImmuCell’s understanding that the FDA is now declining to approve the NADA because the contract manufacturer has not satisfactorily addressed inspectional deficiencies.

After considering the practical implications of the resulting delays, including the pending expiration of ImmuCell’s contract with the manufacturer in March 2026, ImmuCell has decided to pause further investment in Re-Tain® and increase its investment in its market leading First Defense® franchise, which it believes to have significant revenue and profit growth capacity.

ImmuCell will complete ongoing investigational studies with Re-Tain® to assess opportunities for an improved set of claims for preventing and treating mastitis in dairy cows. It will seek to license the product to interested parties or, depending on the outcome of the studies, may seek to partner with a global manufacturer. Neither approach would require further capital investment or in-house manufacturing capability, meaning that ImmuCell will prioritize cash and other resources for maximizing the value of its market leading First Defense® franchise.

“While it is disappointing news that we will be unable to achieve NADA approval with this contract manufacturer, this has only strengthened our resolve to allocate our resources to our highest return opportunity, namely First Defense®,” said Olivier te Boekhorst, President and Chief Executive Officer of ImmuCell. “We will focus on maximizing our opportunities in the estimated $900 million worldwide Total Addressable Market for preventing scours in calves. Based on feedback from customers about our products and our ongoing internal assessment of potential manufacturing efficiencies, we believe there is significant runway for top-line growth and margin expansion for First Defense® that would drive sustainable profit growth for ImmuCell.”

ImmuCell’s First Defense® product line is based on proprietary colostrum hyper-immunization technology, offering a unique range of products with considerable growth potential. The brand holds strong leadership in the U.S. market, shown by its #1 ranking for scour-prevention in the 2025 Hoard’s Dairyman Continuing Market Study and its 29% share of U.S. spend on scours prevention, and targets a sector where high calf values present significant opportunities in dairy and beef industries. ImmuCell believes it is in a favorable position to expand sales internationally and to develop new products by harnessing the special antibody-rich and bioactive properties of colostrum.

“As a result of this strategic change in focus, ImmuCell expects to record a non-cash impairment write-down of property, plant and equipment during the fourth quarter of 2025. As previously disclosed, net book value of Re-Tain® assets was approximately $15.5 million as of September 30, 2025. We are anticipating adjustments to laboratory and manufacturing equipment and construction in progress, resulting in an estimated non-cash impact to profit of approximately $2.3 million. The final figure for this non-cash expense will be determined after a review of alternate purposing and net realizable value is completed as part of the financial closing for the quarter and year ending December 31, 2025,” says Timothy Fiori, Chief Financial Officer. “We plan to repurpose facilities and a large portion of the equipment for the expansion of First Defense® capacity to maximize return on these assets.”

“We are pleased to announce immediate steps toward First Defense® commercial and manufacturing expansion,” added Mr. te Boekhorst. “We have created two new sales territories in the U.S., and we are hiring a senior dairy executive to execute our international strategy. We have also started a multi-year manufacturing improvement program to lower product costs, improve manufacturing yields, and execute our next phase of capacity expansion. Customer feedback and our own market assessments give us confidence that this is the right time for further investment in First Defense®.”

David S. Tomsche, DVM, Chair of the ImmuCell Board of Directors, commented, “Fifteen years ago, ImmuCell established a small field team that grew First Defense® annual revenue from approximately $4.4 million then to approximately $27.8 million in the trailing twelve-month period ended September 30, 2025. First Defense®’s record of more than 13% compounded growth per year for more than a decade gives us confidence that focusing on and investing more in First Defense® can deliver strong shareholder value.”

ImmuCell expects to announce its topline revenue results for the quarter and year ending December 31, 2025 on Thursday, January 8, 2026. ImmuCell expects to host a conference call to discuss revenue results and certain balance sheet activities on Friday, January 9, 2026 at 9:00 AM ET. ImmuCell expects to announce its full financial results for the year ending December 31, 2025 on Wednesday, February 25, 2026. ImmuCell expects to host a conference call to discuss its financial results for the year ending December 31, 2025 on Thursday, February 26, 2026 at 9:00 AM ET.

Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement):

This Press Release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and often include words such as “expects”, “may”, “anticipates”, “aims”, “intends”, “would”, “could”, “should”, “will”, “plans”, “believes”, “estimates”, “targets”, “projects”, “forecasts”, “seeks” and similar words and expressions. Such statements include, but are not limited to, any forward-looking statements relating to: our plans, goals and strategies for our business; the expected timing of key future events; future operational performance and financial results; future demand for our products; the timing and outcome of pending or anticipated applications for regulatory approvals; and any other statements that are not historical facts. Such statements involve known and unknown risks and uncertainties that may cause ImmuCell’s actual results, financial or operational performance or achievements to be materially different from those expressed or implied by these forward-looking statements. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

About ImmuCell:

ImmuCell Corporation’s (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, which provides Immediate Immunity™ to newborn dairy and beef calves. Press releases and other information about ImmuCell are available at: http://www.immucell.com.

Contacts:  Olivier te Boekhorst, President and CEO
  Timothy Fiori, Chief Financial Officer
  ImmuCell Corporation
  investor.relations@ImmuCell.com
   
  Joe Diaz, Robert Blum and Joe Dorame
  Lytham Partners, LLC
  iccc@lythampartners.com

WORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective December 29, 2025

WORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective December 29, 2025




WORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective December 29, 2025

Hangzhou, China, Dec. 24, 2025 (GLOBE NEWSWIRE) — WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it will effect a reverse stock split of its ordinary shares on a 1-for-100 basis (the “Reverse Stock Split”). The Company’s Class A ordinary shares will begin trading on a post-split basis when the market opens on December 29, 2025. The Company’s Class A ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol “WOK,” with a new CUSIP number G9767H125.

The Reverse Stock Split has been approved by the Company’s shareholders and the Company’s board of directors, and is being effectuated primarily to maintain compliance with Nasdaq Marketplace Rule 5550(a)(2) relating to the maintenance of the minimum bid price per share of the Company’s Class A ordinary shares.

Any fractional shares that would have otherwise resulted from the Reverse Stock Split will be rounded up to the next whole number and no fractional shares will be issued. The Reverse Stock Split affects all shareholders uniformly and will not alter any shareholder’s percentage interest in the Company’s outstanding ordinary shares, except for adjustments that may result from the rounding up of fractional shares.

Upon the effectiveness of the Reverse Stock Split, every one hundred shares of the Company’s issued and outstanding Class A ordinary shares as of the effective date will automatically be combined into one Class A ordinary share, and every one hundred shares of the Company’s issued and outstanding Class B ordinary shares as of the effective date will automatically be combined into one Class B ordinary share.

About WORK Medical Technology Group LTD

WORK Medical Technology Group LTD, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, is a supplier of medical devices that develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices through operating subsidiaries in China. The Company has a diverse product portfolio comprising 21 products, including customized and multifunctional masks and other medical consumables. All the products have been sold in 34 provincial-level administrative regions in China, with 15 of them sold in more than 30 countries worldwide. The Company has received a number of quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration allowing their products to enter the U.S. market. For more information, please visit the Company’s website: https://www.workmedtech.com/corporate.

Forward-Looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any forward-looking statements in this press release are based on the Company’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results set forth in the Company’s annual report on Form 20-F and other documents filed by the Company with the U.S. Securities and Exchange Commission. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

For more information, please contact:

WORK Medical Technology Group LTD
Investor Relations Department
Email: ir@workmedtech.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com